The American Academy of Neurology (AAN) Annual Meeting brings together an international attendance of the neurology committee to promote the highest quality patient-centered neurologic care, convey the latest advances, and enhance career satisfaction.
Cognitive Outcome Measures May Help Predict Disease-Modifying Therapy Response in MSMay 3rd 2022
Using this new methodology, 78% of patients with progressive multiple sclerosis demonstrated large treatment benefits with the siponimod (Mayzent; Novartis) on at least 1 of 4 clinical outcomes.
Predicting Patient Response to MS Treatment Using Cognitive Outcome Measures: Ludwig Kappos, MD, FEAN, FAANMay 2nd 2022
The professor of neurology at the University of Basel provided insight on a new methodology that allows depiction of patient profiles from baseline characteristics and their associations with individual outcomes. [WATCH NOW: 5 minutes]
Regenerative Medicine for Neurologic Injury and the Potential of SB623April 29th 2022
Peter J. McAllister, MD, FAAN, medical director and chief medical officer, New England Center for Neurology and Headache, offered his insight into data from the phase 2 STEMTRA trial in TBI and the trends he’s observed in the field of regenerative medicine.
AAN Annual Meeting 2022: Top Expert InterviewsApril 28th 2022
Expert clinicians offer their insight on the associations between stroke and COVID-19, treatment for traumatic brain injury, the latest on aducanumab, priorities for research in migraine, and more, from the 2022 American Academy of Neurology Annual Meeting.
Patient Survey Suggests Preference for Once-Nightly Dosing With FT218 in NarcolepsyApril 27th 2022
Patients who switched from a twice-nightly stable regimen of Xyrem or Xywav to once-nightly FT218 reported that they preferred the new dosing schedule, along with challenges in adherence to twice-nightly dosing.
NeuroVoices: Mark Lew, MD, on Exploring Reflex Tears as a Biomarker for Parkinson DiseaseApril 27th 2022
The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the phenomenon behind reflex tears and whether they can serve as a valuable biomarker for Parkinson disease.
Addition of Mechanical Thrombectomy Improves Odds of Good Outcome in Elderly Poststroke PatientsApril 26th 2022
Following respective improvements in odds of good and poor outcomes, investigators concluded that the addition of mechanical thrombectomy should be considered over best medical management practices alone.
Aligning Patient, Clinician, and Caregiver Goals in Alzheimer Disease: Sharon Cohen, MD, FRCPCApril 26th 2022
The neurologist and assistant professor at the University of Toronto discussed why elevating the voices of patients and caregivers is important to understanding and treating an individual with Alzheimer disease. [WATCH TIME: 3 minutes]
Idiopathic Hypersomnia Demonstrates Moderate to Severe Impact on Quality of Life, Patient-Reported OutcomesApril 25th 2022
Despite a low percentage of patients missing work time due to their condition, a higher percentage reported impairment while working, overall work impairment, and activity impairment.
Treatment Optimization in Epilepsy and the Need to Individualize the ApproachApril 24th 2022
Jacqueline A. French, MD, discussed the factors that influence the challenges in treatment selection in epilepsy, and how patient conversations and comprehension of heterogeneity can help in the treatment selection process.
Understanding the Effects of Polyunsaturated Fatty Acids on Multiple Sclerosis: Ludwig Kappos, MD, FEAN, FAANApril 24th 2022
The professor of neurology at the University of Basel discussed a recent study presented at AAN 2022 on whether levels of polyunsaturated fatty acids are associated with MS disease activity or progression. [WATCH TIME: 4 minutes]
Ofatumumab Shows Decreased Effect on Microglial Activation in Relapsing Multiple SclerosisApril 24th 2022
Patients treated with ofatumumab (Kesimpta; Novartis) demonstrated significant decreases in absolute and percent CD19 counts at day 5 of treatment, which persisted through the 90-day period.
Reasons for Selecting Certain Outcome Measures in Aducanumab’s Drug Development: Sharon Cohen, MD, FRCPCApril 22nd 2022
The neurologist and assistant professor at the University of Toronto provided insight on the differences between outcome measures for Alzheimer disease and how they factored into a new item-level analysis of aducanumab (Aduhelm; Biogen). [WATCH TIME: 3 minutes]
Building the Next Generation of Migraine Specialists: Rashmi B. Halker-Singh, MD, FAAN, and Paul Mathew, MD, DNBPAS, FAAN, FAHSApril 21st 2022
The chair and vice-chair of the Headache and Facial Pain Section of the American Academy of Neurology provided insight on projects they feel are needed to advance the care of patients with migraine-related disorders. [WATCH TIME: 4 minutes]
Details of Item-Level Analysis of Aducanumab at AAN 2022: Sharon Cohen, MD, FRCPCApril 20th 2022
The neurologist and assistant professor at the University of Toronto detailed findings from a new analysis that supports meaningful treatment effect with aducanumab in Alzheimer disease. [WATCH TIME: 6 minutes]
The New Bar Set for Therapies in Treatment-Resistant Epilepsy: Jacqueline A. French, MDApril 19th 2022
The codirector of Epilepsy Clinical Trials at NYU Langone spoke to the progress that’s been made in treating refractory epilepsy and her hopes for the future of drug development in this area of medicine. [WATCH TIME: 5 minutes]
Exploring Repurposed Therapeutics to Treat COVID-19: Jennifer Frontera, MDApril 19th 2022
The professor of neurology at NYU Langone Grossman School of Medicine discussed what high-potential repurposed medications could be an option to treat symptoms of COVID-19 and the realistic possibility of clinical trials. [WATCH TIME: 4 minutes]
Top Priorities Within the Migraine Field: Rashmi B. Halker-Singh, MD, FAAN, and Paul Mathew, MD, DNBPAS, FAAN, FAHSApril 18th 2022
The chair and vice-chair of the Headache and Facial Pain Section of the American Academy of Neurology discussed some of the key research needs for migraine care going forward. [WATCH TIME: 3 minutes]
Ublixtumab’s Effect on Measures of MS Disability: Bruce Cree, MD, PhD, MAS, FAANApril 17th 2022
The clinical research director of the UCSF Multiple Sclerosis Center discussed the recently presented analysis on ublituximab’s effect on disability in relapsing MS and the critical need to focus on improving quality of life. [WATCH TIME: 4 minutes]
The Progress Made in Stem Cell Therapy, Regenerative Medicine: Peter J. McAllister, MD, FAANApril 14th 2022
The medical director and chief medical officer of the New England Center for Neurology and Headache discussed notable data from the STEMTRA trial, and the progress made in the field of regenerative medicine. [WATCH TIME: 2 minutes]
Multilevel Impact Fenfluramine’s Approval Brings to Lennox-Gastaut SyndromeApril 14th 2022
As a primary investigator for fenfluramine’s pivotal phase 3 program, Kelly Knupp, MD, MSCS, FAES, provided insight on new results presented at AAN 2022, as well as the positive ripple effect its recent approval brings to patients with Lennox-Gastaut syndrome.
Gamma Sensory Stimulation Demonstrates Efficacy in Alzheimer Disease in New AnalysisApril 13th 2022
In addition to demonstrating significant differences in slowing functional decline, those on gamma sensory stimulation also demonstrated a significant reduction in brain atrophy relative to the sham group in the OVERTURE study.
Understanding the Associations of Stroke and COVID-19: Matthew Schindler, MD, PhDApril 13th 2022
The assistant professor of neurology at the University of Pennsylvania discussed stroke risk among patients with COVID-19 and the need to seek neurological consultation. [WATCH TIME: 3 minutes]
Relaying Messages About Long-Term Effects of COVID-19: Jennifer Frontera, MDApril 11th 2022
The professor of neurology at NYU Langone Grossman School of Medicine broke down the knowns and unknowns about long-term changes related to COVID-19, their legitimacy, and associations with neurodegenerative disorders. [WATCH TIME: 6 minutes]
Ofatumumab Shows Long-term Safety and Efficacy, Does Not Restrict COVID-19 Vaccine Immune ResponseApril 10th 2022
Data presented at the 2022 AAN Annual Meeting from the ALITHIOS and KYRIOS trials suggest that ofatumumab (Kesimpta; Novartis), an anti-CD20 therapy, is safe with up to 4 years of treatment and does not prevent the mounting of an immune response to mRNA vaccines.
Losmapimod Shows Significant Effect on Facioscapulohumeral Muscular Dystrophy Despite Unchanged BiomarkersApril 10th 2022
After showing several significant differences between placebo, the company has planned a phase 3 study that will assess the therapeutic in a cohort of 230 adults with FSHD.